PDCD1 and non-small cell lung carcinoma: At first glance, this ORR compares favorably to similar ICI combinations (e.g., anti-PD-1/CTLA-4, Checkmate-227/NCT02477826) and is comparable to anti-PD-1 + chemotherapy (Keynote-189/NCT02578680) in a similar NSCLC patient subset (N=202 patients) (161).